Fair Value Measurements (Acquisition of CyDex) (Details) (Cydex Pharmaceuticals, Inc, USD $)
In Millions, unless otherwise specified |
9 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|
Sep. 30, 2014
|
Dec. 31, 2013
|
|||||
Credit Derivatives [Line Items] | ||||||
Amount Of Revenue For Contingent Consideration | $ 15 | |||||
Contingent Consideration Classified as Equity
|
||||||
Credit Derivatives [Line Items] | ||||||
Revenue volatility | 25.00% | 25.00% | ||||
Average of probability of commercialization | 83.80% | 67.60% | ||||
Sales beta | 0.60 | 0.60 | ||||
Credit rating | B | BBB | ||||
Equity risk premium | 6.00% | 6.00% | ||||
Minimum | Contingent Consideration Classified as Equity
|
||||||
Credit Derivatives [Line Items] | ||||||
Range of annual revenue subject to revenue sharing | 17.9 | [1] | 4.2 | [1] | ||
Maximum | Contingent Consideration Classified as Equity
|
||||||
Credit Derivatives [Line Items] | ||||||
Range of annual revenue subject to revenue sharing | $ 20.5 | [1] | $ 19.8 | [1] | ||
|